Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Upgrade
Baird upgrades Vertex Pharmaceuticals, shares attractive ahead of readouts » 08:16
02/23/21
02/23
08:16
02/23/21
08:16
VRTX

Vertex Pharmaceuticals

$215.14 /

+8.05 (+3.89%)

As reported previously,…

As reported previously, Baird analyst Brian Skorney upgraded Vertex Pharmaceuticals to Outperform from Neutral with a price target of $252, up from $220. The analyst said the shares were attractive ahead of several readouts and is supported by the CF opportunity. He said any positive news flow for the pipeline has the potential to provide significant upside to the shares.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$215.14 /

+8.05 (+3.89%)

VRTX Vertex Pharmaceuticals
$215.14 /

+8.05 (+3.89%)

02/23/21 Baird
Vertex Pharmaceuticals upgraded to Outperform from Neutral at Baird
02/02/21 Credit Suisse
Vertex Pharmaceuticals price target lowered to $280 from $285 at Credit Suisse
02/02/21 BMO Capital
Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital
02/02/21 H.C. Wainwright
Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright
VRTX Vertex Pharmaceuticals
$215.14 /

+8.05 (+3.89%)

VRTX Vertex Pharmaceuticals
$215.14 /

+8.05 (+3.89%)

VRTX Vertex Pharmaceuticals
$215.14 /

+8.05 (+3.89%)

VRTX Vertex Pharmaceuticals
$215.14 /

+8.05 (+3.89%)

Upgrade
Vertex Pharmaceuticals upgraded to Outperform from Neutral at Baird » 05:27
02/23/21
02/23
05:27
02/23/21
05:27
VRTX

Vertex Pharmaceuticals

$215.14 /

+8.05 (+3.89%)

Baird analyst Brian…

Baird analyst Brian Skorney upgraded Vertex Pharmaceuticals to Outperform from Neutral with a price target of $252, up from $220.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$215.14 /

+8.05 (+3.89%)

VRTX Vertex Pharmaceuticals
$215.14 /

+8.05 (+3.89%)

02/02/21 Credit Suisse
Vertex Pharmaceuticals price target lowered to $280 from $285 at Credit Suisse
02/02/21 BMO Capital
Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital
02/02/21 H.C. Wainwright
Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright
02/02/21 Piper Sandler
Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler
VRTX Vertex Pharmaceuticals
$215.14 /

+8.05 (+3.89%)

VRTX Vertex Pharmaceuticals
$215.14 /

+8.05 (+3.89%)

VRTX Vertex Pharmaceuticals
$215.14 /

+8.05 (+3.89%)

VRTX Vertex Pharmaceuticals
$215.14 /

+8.05 (+3.89%)

Hot Stocks
Vertex study of VX-864 completes enrollment, Clinicaltrials.gov shows » 12:59
02/22/21
02/22
12:59
02/22/21
12:59
VRTX

Vertex Pharmaceuticals

$214.90 /

+7.81 (+3.77%)

Vertex…

Vertex Pharmaceuticals' study evaluating the efficacy, safety and pharmacokinetics of VX-864 in subjects with a PiZZ genotype has completed enrollment, according to an update on Clinicaltrials.gov. STAT's Adam Feuerstein tweeted:" $VRTX VX-864 clinical trial patient enrollment completed, suggesting no liver tox issues." Shares of Vertex are up 4% to $215.40 in afternoon trading. Reference Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$214.90 /

+7.81 (+3.77%)

VRTX Vertex Pharmaceuticals
$214.90 /

+7.81 (+3.77%)

02/02/21 Credit Suisse
Vertex Pharmaceuticals price target lowered to $280 from $285 at Credit Suisse
02/02/21 BMO Capital
Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital
02/02/21 H.C. Wainwright
Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright
02/02/21 Piper Sandler
Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler
VRTX Vertex Pharmaceuticals
$214.90 /

+7.81 (+3.77%)

VRTX Vertex Pharmaceuticals
$214.90 /

+7.81 (+3.77%)

VRTX Vertex Pharmaceuticals
$214.90 /

+7.81 (+3.77%)

VRTX Vertex Pharmaceuticals
$214.90 /

+7.81 (+3.77%)

Hot Stocks
Freeline appoints Michael Parini as president, COO » 07:23
02/16/21
02/16
07:23
02/16/21
07:23
FRLN

Freeline

$15.64 /

+0.1 (+0.64%)

, VRTX

Vertex Pharmaceuticals

$214.26 /

+3.75 (+1.78%)

Freeline Therapeutics…

Freeline Therapeutics (FRLN) announced the expansion of its executive leadership team with the appointment of Michael Parini to the newly-created role of President and COO. This appointment complements the recent hires of Stephen Diamond, Jr. as SVP and General Counsel and David Arrington as VP of Investor Relations and Corporate Communications. Michael Parini has been appointed to the role of President and COO, effective March 15, 2021. Parini will be based in the US and will report to CEO. Theresa Heggie, supporting her in executing the Company's global strategy and overseeing critical business and operational functions. These functions include Program Management, Corporate Strategy, Business Development, Legal, Compliance, Investor Relations, Corporate Communications and Information Technology. Parini brings more than 20 years of executive experience in the biopharmaceutical industry, including most recently at Vertex Pharmaceuticals (VRTX), where he served as Executive Vice President and Chief Administrative, Legal and Business Development Officer.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$214.26 /

+3.75 (+1.78%)

FRLN Freeline
$15.64 /

+0.1 (+0.64%)

FRLN Freeline
$15.64 /

+0.1 (+0.64%)

11/25/20 Redburn
Freeline initiated with a Neutral at Redburn
09/01/20 Evercore ISI
Freeline initiated with an Outperform at Evercore ISI
09/01/20 Wedbush
Wedbush bullish on Freeline, initiates with an Outperform
09/01/20 Wedbush
Freeline initiated with an Outperform at Wedbush
VRTX Vertex Pharmaceuticals
$214.26 /

+3.75 (+1.78%)

02/02/21 Credit Suisse
Vertex Pharmaceuticals price target lowered to $280 from $285 at Credit Suisse
02/02/21 BMO Capital
Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital
02/02/21 H.C. Wainwright
Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright
02/02/21 Piper Sandler
Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler
VRTX Vertex Pharmaceuticals
$214.26 /

+3.75 (+1.78%)

  • 07
    Aug
VRTX Vertex Pharmaceuticals
$214.26 /

+3.75 (+1.78%)

VRTX Vertex Pharmaceuticals
$214.26 /

+3.75 (+1.78%)

VRTX Vertex Pharmaceuticals
$214.26 /

+3.75 (+1.78%)

Periodicals
Amicus, BioMarin speculated by Dealreporter as possible Vertex targets » 10:07
02/02/21
02/02
10:07
02/02/21
10:07
VRTX

Vertex Pharmaceuticals

$223.16 /

-8.55 (-3.69%)

, FOLD

Amicus

$19.25 /

+ (+0.00%)

, BMRN

BioMarin

$83.36 /

+0.26 (+0.31%)

Following the latest…

Following the latest earnings call from Vertex Pharmaceuticals (VRTX), Dealreporter told its subscribers that questions about what the company is going to buy "do not appear to be going away anytime soon," contacts tell The Fly. The deal-focused publication notes that is has previously highlighted Amicus Therapeutics (FOLD) "as a potential name to keep an eye on" in light of Vertex's previous interest in the gene therapy space, adding that "maybe this is the year that longtime rare disease takeover target" Biomarin Pharmaceutical (BMRN) gets a "serious look" if Vertex "wanted to swing for the fences," contacts tell The Fly.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$223.16 /

-8.55 (-3.69%)

FOLD Amicus
$19.25 /

+ (+0.00%)

BMRN BioMarin
$83.36 /

+0.26 (+0.31%)

VRTX Vertex Pharmaceuticals
$223.16 /

-8.55 (-3.69%)

02/02/21 Credit Suisse
Vertex Pharmaceuticals price target lowered to $280 from $285 at Credit Suisse
02/02/21 BMO Capital
Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital
02/02/21 H.C. Wainwright
Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright
02/02/21 Piper Sandler
Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler
FOLD Amicus
$19.25 /

+ (+0.00%)

01/22/21 JPMorgan
Amicus remains top idea into 'meaningful catalyst' at JPMorgan
01/04/21 Cowen
Amicus could move 30%-40% on Pompe study data, says Cowen
12/28/20 Cantor Fitzgerald
Amicus assumed with an Overweight at Cantor Fitzgerald
12/14/20 JPMorgan
JPMorgan boosts Amicus target to $29, adds to Analyst Focus List
BMRN BioMarin
$83.36 /

+0.26 (+0.31%)

01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
01/11/21 Baird
BioMarin price target raised to $110 from $100 at Baird
12/21/20 Piper Sandler
BioMarin data today should ease approvability concerns, says Piper Sandler
12/17/20 JPMorgan
BioMarin remains 'highest conviction name' at JPMorgan
VRTX Vertex Pharmaceuticals
$223.16 /

-8.55 (-3.69%)

FOLD Amicus
$19.25 /

+ (+0.00%)

BMRN BioMarin
$83.36 /

+0.26 (+0.31%)

VRTX Vertex Pharmaceuticals
$223.16 /

-8.55 (-3.69%)

VRTX Vertex Pharmaceuticals
$223.16 /

-8.55 (-3.69%)

FOLD Amicus
$19.25 /

+ (+0.00%)

BMRN BioMarin
$83.36 /

+0.26 (+0.31%)

VRTX Vertex Pharmaceuticals
$223.16 /

-8.55 (-3.69%)

BMRN BioMarin
$83.36 /

+0.26 (+0.31%)

Recommendations
Vertex Pharmaceuticals price target lowered to $280 from $285 at Credit Suisse » 08:07
02/02/21
02/02
08:07
02/02/21
08:07
VRTX

Vertex Pharmaceuticals

$231.79 /

+2.77 (+1.21%)

Credit Suisse analyst…

Credit Suisse analyst Evan Seigerman lowered the firm's price target on Vertex Pharmaceuticals to $280 from $285 and keeps an Outperform rating on the shares following quarterly results. The analyst notes that while Q4 results were "fine" - modest revenue beat, and a slight EPS miss -, investor focus has turned to business development.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

02/02/21 BMO Capital
Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital
02/02/21 H.C. Wainwright
Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright
02/02/21 Piper Sandler
Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler
01/12/21 Truist
Crispr Therapeutics price target raised to $210 from $170 at Truist
VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

Recommendations
Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital » 06:57
02/02/21
02/02
06:57
02/02/21
06:57
VRTX

Vertex Pharmaceuticals

$231.79 /

+2.77 (+1.21%)

BMO Capital analyst Do…

BMO Capital analyst Do Kim lowered the firm's price target on Vertex Pharmaceuticals to $284 from $302 but keeps an Outperform rating on the shares. The analyst notes that while the company's FY21 product revenue guidance looks "conservative", he is lowering his EPS view to $11.83 from $12.23. Kim still keeps the $10B or more in peak sales estimate for Vertex and believes that its Trikafta/Kaftrio will continue to grow this year. The analyst adds that the company's pipeline progress, starting with VX-86 phase 2 trial data in the first half of this year, could begin adding "pipeline value".

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

02/02/21 H.C. Wainwright
Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright
02/02/21 Piper Sandler
Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler
01/12/21 Truist
Crispr Therapeutics price target raised to $210 from $170 at Truist
12/30/20
Fly Intel: Top five analyst calls
VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

Recommendations
Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright » 06:31
02/02/21
02/02
06:31
02/02/21
06:31
VRTX

Vertex Pharmaceuticals

$231.79 /

+2.77 (+1.21%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein lowered the firm's price target on Vertex Pharmaceuticals to $275 from $315 and keeps a Buy rating on the shares to reflect the company's provided revenue guidance for 2021.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

02/02/21 Piper Sandler
Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler
01/12/21 Truist
Crispr Therapeutics price target raised to $210 from $170 at Truist
12/30/20
Fly Intel: Top five analyst calls
12/30/20 Daiwa
Vertex Pharmaceuticals initiated with an Outperform at Daiwa
VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

Recommendations
Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler » 05:06
02/02/21
02/02
05:06
02/02/21
05:06
VRTX

Vertex Pharmaceuticals

$231.79 /

+2.77 (+1.21%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Vertex Pharmaceuticals to $347 from $307 and reiterates an Overweight rating on the shares following the company's Q4 results. The analyst says "strong" cystic fibrosis sales will fund Vertex's "emerging" early stage pipeline.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

01/12/21 Truist
Crispr Therapeutics price target raised to $210 from $170 at Truist
12/30/20
Fly Intel: Top five analyst calls
12/30/20 Daiwa
Vertex Pharmaceuticals initiated with an Outperform at Daiwa
12/10/20 Oppenheimer
Crispr Therapeutics price target raised to $165 from $155 at Oppenheimer
VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

On The Fly
Fly Intel: After-Hours Movers » 19:13
02/01/21
02/01
19:13
02/01/21
19:13
SKY

Skyline Champion

$34.99 /

+1.29 (+3.83%)

, KMT

Kennametal

$39.05 /

+1.2 (+3.17%)

, HLIT

Harmonic

$7.87 /

+0.08 (+1.03%)

, CRUS

Cirrus Logic

$97.99 /

+4.155 (+4.43%)

, RMBS

Rambus

$19.55 /

+0.51 (+2.68%)

, WWD

Woodward

$115.35 /

+3.32 (+2.96%)

, VRTX

Vertex Pharmaceuticals

$231.79 /

+2.77 (+1.21%)

, ARQT

Arcutis Biotherapeutics

$35.37 /

+7.95 (+28.99%)

, NXPI

NXP Semiconductors

$171.63 /

+11.4 (+7.11%)

, MITK

Mitek Systems

$16.85 /

+0.71 (+4.40%)

, CURI

CuriosityStream

$17.80 /

+0.39 (+2.24%)

, RVMD

Revolution Medicines

$44.71 /

+2.41 (+5.70%)

, AXTA

Axalta Coating

$27.77 /

+0.77 (+2.85%)

Check out this evening's…

ShowHide Related Items >><<
WWD Woodward
$115.35 /

+3.32 (+2.96%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

RVMD Revolution Medicines
$44.71 /

+2.41 (+5.70%)

RMBS Rambus
$19.55 /

+0.51 (+2.68%)

NXPI NXP Semiconductors
$171.63 /

+11.4 (+7.11%)

MITK Mitek Systems
$16.85 /

+0.71 (+4.40%)

KMT Kennametal
$39.05 /

+1.2 (+3.17%)

HLIT Harmonic
$7.87 /

+0.08 (+1.03%)

CURI CuriosityStream
$17.80 /

+0.39 (+2.24%)

CRUS Cirrus Logic
$97.99 /

+4.155 (+4.43%)

AXTA Axalta Coating
$27.77 /

+0.77 (+2.85%)

ARQT Arcutis Biotherapeutics
$35.37 /

+7.95 (+28.99%)

SKY Skyline Champion
$34.99 /

+1.29 (+3.83%)

12/18/20 Barclays
Skyline price target raised to $36 from $32 at Barclays
12/18/20 Wedbush
Skyline initiated with an Outperform at Wedbush
12/17/20 Wedbush
Skyline initiated with an Outperform at Wedbush
05/21/20 Truist
Skyline upgraded to Buy from Hold at SunTrust
KMT Kennametal
$39.05 /

+1.2 (+3.17%)

01/15/21 Jefferies
Kennametal price target raised to $48 from $40 at Jefferies
01/05/21 Barclays
Kennametal price target raised to $35 from $33 at Barclays
12/29/20 Barclays
Short cycle industrial risk/rewards more balanced into 2021, says Barclays
11/04/20
Fly Intel: Top five analyst downgrades
HLIT Harmonic
$7.87 /

+0.08 (+1.03%)

01/14/21 Barclays
Harmonic price target raised to $8 from $7 at Barclays
09/23/20 Colliers
Harmonic opportunity in focus after SES partners with Microsoft, says Colliers
06/01/20 JPMorgan
Harmonic downgraded to Neutral on spending pushouts at JPMorgan
06/01/20 JPMorgan
Harmonic downgraded to Neutral from Overweight at JPMorgan
CRUS Cirrus Logic
$97.99 /

+4.155 (+4.43%)

01/28/21 Oppenheimer
Strength in Apple iPhone sales bodes well for Qorvo, Skyworks, says Oppenheimer
01/12/21 Susquehanna
Susquehanna names top five M&A candidates in Semi space
01/08/21 Barclays
Cirrus Logic price target raised to $90 from $70 at Barclays
01/06/21 KeyBanc
Cirrus Logic upgraded to Overweight from Sector Weight at KeyBanc
RMBS Rambus
$19.55 /

+0.51 (+2.68%)

01/25/21 Citi
Rambus price target raised to $24 from $17 at Citi
01/12/21 Wells Fargo
Intel's ramp of Ice Lake should be a boost for Rambus, says Wells Fargo
12/30/20 Roth Capital
Rambus price target raised to $21 from $18 at Roth Capital
09/25/20 Citi
KLA on top, Amkor at bottom of Citi's Semiconductor rankings
WWD Woodward
$115.35 /

+3.32 (+2.96%)

01/11/21 Truist
Woodward upgraded to Hold from Sell at Truist
12/13/20 Goldman Sachs
Woodward initiated with a Neutral at Goldman Sachs
12/04/20 Barclays
Woodward downgraded to Equal Weight from Overweight at Barclays
11/20/20 Truist
Woodward price target raised to $70 from $51 at Truist
VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

01/12/21 Truist
Crispr Therapeutics price target raised to $210 from $170 at Truist
12/30/20
Fly Intel: Top five analyst calls
12/30/20 Daiwa
Vertex Pharmaceuticals initiated with an Outperform at Daiwa
12/10/20 Oppenheimer
Crispr Therapeutics price target raised to $165 from $155 at Oppenheimer
ARQT Arcutis Biotherapeutics
$35.37 /

+7.95 (+28.99%)

02/01/21 Cowen
Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
01/28/21 JonesTrading
Arcutis Biotherapeutics initiated with a Buy at JonesTrading
11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
NXPI NXP Semiconductors
$171.63 /

+11.4 (+7.11%)

02/01/21 BMO Capital
NXP Semiconductors price target raised to $168 from $142 at BMO Capital
01/26/21 Wells Fargo
NXP Semiconductors price target raised to $200 from $180 at Wells Fargo
01/26/21 Barclays
NXP Semiconductors price target raised to $200 from $150 at Barclays
01/15/21 Truist
NXP Semiconductors price target raised to $209 from $165 at Truist
MITK Mitek Systems
$16.85 /

+0.71 (+4.40%)

01/22/21 Maxim
Mitek Systems initiated with a Buy at Maxim
12/04/20 Benchmark
Mitek Systems CFO exit plan adds uncertainty, says Benchmark
08/24/20 William Blair
Mitek long-term risk/reward prospects attractive, says William Blair
03/25/20 National Securities
Mitek Systems upgraded to Buy from Neutral at National Securities
CURI CuriosityStream
$17.80 /

+0.39 (+2.24%)

01/12/21 Benchmark
CuriosityStream initiated with a Buy at Benchmark
01/06/21 B. Riley Securities
B. Riley downgrades CuriosityStream after 'puzzling' 95% stock rally
01/06/21 B. Riley Securities
CuriosityStream downgraded to Neutral from Buy at B. Riley Securities
12/21/20 Stifel
CuriosityStream downgraded to Hold from Buy at Stifel
RVMD Revolution Medicines
$44.71 /

+2.41 (+5.70%)

01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
05/21/20
Fly Intel: Top five analyst initiations
AXTA Axalta Coating
$27.77 /

+0.77 (+2.85%)

01/15/21 KeyBanc
Axalta Coating downgraded to Sector Weight from Overweight at KeyBanc
10/23/20 Deutsche Bank
Axalta Coating price target raised to $30 from $26 at Deutsche Bank
10/20/20 Morgan Stanley
Axalta Coating price target raised to $27 from $23 at Morgan Stanley
10/14/20
Fly Intel: Top five analyst upgrades
WWD Woodward
$115.35 /

+3.32 (+2.96%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

SKY Skyline Champion
$34.99 /

+1.29 (+3.83%)

RVMD Revolution Medicines
$44.71 /

+2.41 (+5.70%)

RMBS Rambus
$19.55 /

+0.51 (+2.68%)

NXPI NXP Semiconductors
$171.63 /

+11.4 (+7.11%)

MITK Mitek Systems
$16.85 /

+0.71 (+4.40%)

KMT Kennametal
$39.05 /

+1.2 (+3.17%)

HLIT Harmonic
$7.87 /

+0.08 (+1.03%)

CRUS Cirrus Logic
$97.99 /

+4.155 (+4.43%)

AXTA Axalta Coating
$27.77 /

+0.77 (+2.85%)

ARQT Arcutis Biotherapeutics
$35.37 /

+7.95 (+28.99%)

  • 03
    Feb
  • 04
    Feb
  • 02
    Oct
  • 09
    Jul
  • 13
    Feb
VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

MITK Mitek Systems
$16.85 /

+0.71 (+4.40%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

SKY Skyline Champion
$34.99 /

+1.29 (+3.83%)

RMBS Rambus
$19.55 /

+0.51 (+2.68%)

NXPI NXP Semiconductors
$171.63 /

+11.4 (+7.11%)

MITK Mitek Systems
$16.85 /

+0.71 (+4.40%)

HLIT Harmonic
$7.87 /

+0.08 (+1.03%)

CURI CuriosityStream
$17.80 /

+0.39 (+2.24%)

CRUS Cirrus Logic
$97.99 /

+4.155 (+4.43%)

AXTA Axalta Coating
$27.77 /

+0.77 (+2.85%)

ARQT Arcutis Biotherapeutics
$35.37 /

+7.95 (+28.99%)

VRTX Vertex Pharmaceuticals
$231.79 /

+2.77 (+1.21%)

RVMD Revolution Medicines
$44.71 /

+2.41 (+5.70%)

RMBS Rambus
$19.55 /

+0.51 (+2.68%)

NXPI NXP Semiconductors
$171.63 /

+11.4 (+7.11%)

CRUS Cirrus Logic
$97.99 /

+4.155 (+4.43%)

AXTA Axalta Coating
$27.77 /

+0.77 (+2.85%)

ARQT Arcutis Biotherapeutics
$35.37 /

+7.95 (+28.99%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.